6660 Stock Overview
Researches, develops, manufactures, and commercializes of vaccine products for human use in the People’s Republic of China.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
AIM Vaccine Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$4.26 |
| 52 Week High | HK$38.55 |
| 52 Week Low | HK$3.95 |
| Beta | 0 |
| 11 Month Change | -8.78% |
| 3 Month Change | -41.16% |
| 1 Year Change | -89.22% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -92.74% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6660 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 2.9% | 0.2% | 4.1% |
| 1Y | -89.2% | -19.6% | 0.9% |
Return vs Industry: 6660 underperformed the Hong Kong Biotechs industry which returned -19.5% over the past year.
Return vs Market: 6660 underperformed the Hong Kong Market which returned 0.9% over the past year.
Price Volatility
| 6660 volatility | |
|---|---|
| 6660 Average Weekly Movement | 6.8% |
| Biotechs Industry Average Movement | 6.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in HK Market | 13.3% |
| 10% least volatile stocks in HK Market | 3.4% |
Stable Share Price: 6660's share price has been volatile over the past 3 months.
Volatility Over Time: 6660's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 1,557 | Yan Zhou | www.aimbio.com |
AIM Vaccine Co., Ltd. researches, develops, manufactures, and commercializes of vaccine products for human use in the People’s Republic of China. The company’s product pipeline includes tetravalent meningococcal conjugate vaccine, that is in phase IV clinical trials indicated for meningococcal disease 13-Valent pneumonia Conjugate and 23-valent pneumonia Polysaccharide vaccine to treat pneumonia; iterative serum-free rabies vaccine; and bivalent Delta-Omicron BA.5 mRNA COVID-19 vaccine which is in phase III clinical trials to treat COVID-19 infection. It also offers tetravalent meningococcal polysaccharide and conjugate vaccine, that is in phase II trials for the treatment of meningococcal disease; EV71-CA16 Bivalent HFMD vaccine.
AIM Vaccine Co., Ltd. Fundamentals Summary
| 6660 fundamental statistics | |
|---|---|
| Market cap | HK$5.16b |
| Earnings (TTM) | -HK$1.31b |
| Revenue (TTM) | HK$1.31b |
3.9x
P/S Ratio-3.9x
P/E RatioIs 6660 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6660 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.18b |
| Cost of Revenue | CN¥1.84b |
| Gross Profit | -CN¥655.57m |
| Other Expenses | CN¥534.32m |
| Earnings | -CN¥1.19b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.98 |
| Gross Margin | -55.36% |
| Net Profit Margin | -100.48% |
| Debt/Equity Ratio | 51.8% |
How did 6660 perform over the long term?
See historical performance and comparison